17ଲ-acyl-4-aza-5-androst-1-ene-3-ones as 5-reductase inhibitors
August 21, 2009. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 2227876 3239417 3264301 3285918 Preparation of 4-aza-17-substituted-5-androstan-3-ones useful as 5-reductase inhibitors 4-Aza-17ଲ-substituted-5-androstan-3-one-reductase inhibitors Steroidic 5-reductase inhibitors 17ଲ-N-monosubstituted carbamoyl-4-aza-5-androst-1-en-3-ones which are active as testosterone 5-reductase inhibitors Oxidized analogs of 17ଲ-N-monosubstituted-carbamoyl-4-aza-5--androstan-3-ones 17 -Acyl-4-aza-5a-androst-1-en-3-ones as 5 alpha-reductase inhibitors Patent #: 4859681 InventorsAssigneeApplicationNo. 396184 filed on 08/21/1989US Classes:514/284, Tetracyclo ring system having the six-membered hetero ring as one of the cyclos546/77The six-membered hetero ring shares ring members with one other cyclo onlyExaminersPrimary: Rivers, Diana G.Attorney, Agent or FirmForeign Patent References
International ClassesA61K 031/58C07J 073/00 Abstract17ଲ-Acyl-4-aza-5-androst-1-ene-3-ones of the formula ##STR1## wherein R is selected from hydrogen, methyl and ethyl andR2 is monocyclic aryl optionally containing 1 or more lower alkyl substituents of from 1-2 carbon atoms and/or 1 or more halo (Cl or Br) substituents;and R', R" and R'" are each selected from hydrogen and methyl and pharmaceutical formulation of the above compounds are active as testosterone 5-reductase inhibitors and thus are useful for treatment of acne, seborrhea, female hirsutism, androgenic alopecia, prostatic carcinoma and benign prostatic hypertrophy.Other References
|
| ||||||||||||||
